SCHEMBL23354517

SCHEMBL23354517

Cc1c(C(=O)CNC(=O)O)cnn1CC(F)(F)F

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
LMNA P02545 2/20 0.39
HTT P42858 1/20 0.39
P2RX7 Q99572 2/20 0.36
HPGD P15428 1/20 0.35
MAPK1 P28482 2/20 0.35
RAB9A P51151 3/20 0.34
CYP1A2 P05177 2/20 0.34
CYP2C19 P33261 2/20 0.34
CYP3A4 P08684 1/20 0.34
SPR P35270 2/20 0.33
PTGS2 P35354 1/20 0.33
KDM4E B2RXH2 1/20 0.33
PDE10A Q9Y233 1/20 0.33
CCR1 P32246 1/20 0.32
P2RX3 P56373 1/20 0.32
P2RX2 Q9UBL9 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23367091 0.87 SMN1; SMN2 (0.40) ALDH1A1SMN1; SMN2LMNAHTTP2RX7
SCHEMBL24927846 0.85 ALDH1A1 (0.35) ALDH1A1SMN1; SMN2LMNAHTTP2RX7
SCHEMBL23354462 0.81 SMN1; SMN2 (0.41) ALDH1A1SMN1; SMN2LMNAHTTP2RX7
Hydrochloric Acid SCHEMBL23354277 0.80 SMN1; SMN2 (0.40) ALDH1A1SMN1; SMN2LMNAHTTP2RX7
SCHEMBL1841864 0.79 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2LMNAHTTP2RX7
SCHEMBL9901418 0.78 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2LMNAHTTP2RX7
SCHEMBL9903594 0.78 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2LMNAHTTP2RX7
SCHEMBL23354171 0.76 NPC1 (0.46) ALDH1A1SMN1; SMN2LMNAHTTHPGD
SCHEMBL1302838 0.74 SMN1; SMN2 (0.52) ALDH1A1SMN1; SMN2LMNAHPGDRAB9A
SCHEMBL23354368 0.73 MAPK1 (0.35) ALDH1A1SMN1; SMN2HTTP2RX7HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4058448-B1 HYDANTOIN DERIVATIVES AS ADAMTS7 ANTAGONISTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES BAYER AG (DE) 2024-05-29 EP disclosed
US-20230027346-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2023-01-26 US disclosed
EP-4058448-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS Bayer Aktiengesellschaft (DE) 2022-09-21 EP disclosed
WO-2021094436-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2021-05-20 WO disclosed
EP-3822268-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS Bayer Aktiengesellschaft (DE) 2021-05-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230027346-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS ADAMTS7, MMP7, ADAM17 ALDH1A1 3828/4885SMN1; SMN2 3850/4885LMNA 1752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.